Some evidences suggest that telomere restriction fragment length (TRF-L) is an effective indicator of histopathogenesis in B-cell tumors. As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed by Southern blot in 201 patients and compared to variable immunoglobulin heave chain gene mutational status (VH-MS) and to other known prognostic features. Overall survival (OS), time to first treatment (TTFT) and progressionfree survival (PFS) were evaluated. Our results indicate the following: (1) TRF-L is heterogeneous among B-CLL patients (median 6014 bp, range 1465-16 762); (2) TRF-L correlates to VH-MS (r 2 ¼ 0.1994, Po0.0001) with VH-mutated patients showing long and VH-unmutated short telomeres; however, 41% of VH-unmutated and 5% of VH-mutated patients did not show this correlation and were thus defined as 'discordant'; (3) TRF-L effectively predicts outcome in terms of TTFT, PFS and OS; (4) VH-unmutated discordant patients have a better clinical outcome than VH-unmutated concordant patients (OS Po0.01, PFS Po0.05) and similar to that of VH-mutated patients (OS, PFS P ¼ NS). Compared to VH-unmutated concordant patients, VHunmutated discordant patients showed no peculiarity in their immunoglobulin rearrangement nor in their flow cytometry or fluorescence in situ hybridization profile. In conclusion, TRF-L can be helpful to refine prognostication of B-CLL patients, particularly those with a VH-unmutated immunoglobulin sequence.
Introduction
The clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is far from being uniform. It is considered an indolent disease, as its median overall survival (OS) exceeds 10 years. [1] [2] [3] [4] [5] However, several patients have a worse outcome and shortly succumb to this malignancy. 5, 6 Several clinical and biological parameters have been investigated as prognostic indicators: Binet clinical stage, chromosomal abnormalities, variable immunoglobulin heave chain gene mutational status (VH-MS) and ZAP70 expression are the most successful and widely employed. [7] [8] [9] [10] [11] [12] Despite its technical complexity, VH-MS is highly appreciated as prognostic indicator, chiefly because it remains stable throughout the natural history of the disease and objective in its determination. 13, 14 The reason why some B-CLL carry highly mutated VH-genes, whereas others have germline or neargermline sequences is not completely clear. It is believed that the rate of somatic hypermutation is related to the presence and intensity of 'germinal center (GC) experience' undergone by the B-cell in which leukemogenesis occurred. [15] [16] [17] We showed that also telomere restriction fragment length (TRF-L) seems to correlate with GC-experience of mature B-cell disorders. 18 In particular, GC-experienced tumors have longer telomeres than GC-inexperienced tumors. 18 This pattern is consistent in all mature B-cell disorders thus far investigated, including mantle cell, follicular, Burkitt's, diffuse large cell, marginal zone lymphoma, multiple myeloma and B-CLL. This was not unexpected in the latter disease, as a few authors already reported this finding. [19] [20] [21] [22] As histopathogenesis according to GC is a well-known prognostic feature in B-CLL, it is conceivable that TRF-L might also be prognostically significant. This has been shown for OS although it is unknown whether TRF-L could predict also earlier outcome indicators, such as time to first treatment (TTFT) and progression-free survival (PFS). More importantly, TRF-L and VH-MS have been considered mutually dependent, although no extensive characterization of discordance between these two parameters has been performed. In particular, it is unknown if discordant patients belong to some specific prognostic subgroup already identified by flow cytometry and fluorescence in situ hybridization (FISH). In addition, no extensive characterization of the immunoglobulin heavy chain (IgH) rearrangement of these patients has been performed particularly in terms of VH-usage and rate of homology. Finally, although one single report indicates that VH-mutated patients with short telomeres have a worse OS compared to mutated patients with long telomeres, the clinical behavior of these patients need further characterization, particularly as far as the VH-unmutated discordant patients are concerned. 22 This study addressed these issues by evaluating a large population of B-CLL patients who had been followed in the Piedmont area.
Patients and methods

Patients and tumor samples
We analyzed peripheral blood (PB) samples from 201 B-CLL patients diagnosed between 1980 and 2005. Non-viable cells were stored at À701C as dry pellets after a Ficoll-Hypaque density gradient centrifugation. Cells stored with these proce-dures can be employed for DNA-based studies, including Southern blot and polymerase chain reaction (PCR). Genomic DNA was extracted with the DNAzol reagent (Gibco BRL Life technologies, Grand Island, NY, USA) following the manufacturer's recommendations. Patients were diagnosed and followed at three Institutions in the Piedmont area: 140 patients belonged to Divisione di Ematologia, Università di Torino, 30 to Divisione di Ematologia, Ospedale Santa Croce e Carle, Cuneo and 31 to Divisione di Medicina Generale VII -Azienda Ospedaliera S. Giovanni Battista, Torino. However, all the biological studies were centralized at Divisione di Ematologia, Università di Torino. Patients were not included in a clinical trial and thus treated according to their physician choice. However, the three Centers are part of a regional network and follow similar therapeutic algorithms. These guidelines allow treatment start in case of symptomatic disease or white blood cells greater than 200 000/mm 3 . For these patients the treatment modality was as follows: (1) chlorambucil for patients older than 65 years, or unfit, or treated before 1995; (2) a fludarabine-free intravenous regimen (most often consisting of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) for patients that were considered good candidates for autograft at relapse in order to avoid stem cell toxicity; (3) fludarabine the remaining patients. B-CLL diagnosis was made according to the WHO classification and flow cytometry. 23, 24 All samples were taken at diagnosis and were included in the analysis if they displayed more than 80% of CD19 þ /CD5 þ cells, ruling out any bias related to the presence of non-neoplastic contaminating cells. 18 All patients gave written informed consent to the use of PB cells for research purposes. Clinical features and outcome data were available for all patients. CD38 and ZAP70 expression at diagnosis were available in 157 and 111 patients, respectively. Major B-CLL chromosome abnormalities (i.e. chromosome 11, 13, 17 deletions and chromosome 12 trisomy) were assessed by FISH in 161 patients. Patient clinical characteristics are shown in Table 1 . Of note, patients treated with transplant-based regimens were not included the study.
Determination of TRF-L
Peak TRF-L was determined by Southern blot analysis as reported elsewhere. 18, 25 Peak TRF-L was preferred to mean TRF-L as this approach allows accurate measurement of TRF-L in the presence of up to 30% contaminating non-neoplastic cells, as documented by extensive cell dilution studies. 18 Briefly, 2 mg of genomic DNA were digested by mixing HinfI and RsaI (Roche Diagnostics, Mannheim, Germany). TRF were separated by 0.8% agarose gel electrophoresis. Gels were transferred to a positively charged nylon membrane (Roche Diagnostic Mannheim, Germany) and UV cross-linked. Hybridization and detection were performed using the TeloTAGGG Telomere Length Assay Kit (Roche Diagnostics, Mannheim, Germany), as described previously. 18, 25 Membranes were scanned and analyzed with KODAK DIGITAL SCIENCE 1D Software (Scientific Imaging Systems, New Haven, CT, USA). 18, 25 Data on TRF-L were not available to clinicians and did not affect therapeutic decisions.
Cell separation using the CD19 antigen
To exclude that differences in TRF-L could be related to the presence of contaminating non clonal cells, cell separation studies were performed using the CD-19 antigen. Mononuclear cells from PB were separated by Ficoll-Hipaque gradient centrifugation and washed in phosphate-buffered saline (PBS) as suggested by the manufacturer (Miltenyi Biotec Gmbh, Bergisch Gladbach, Germany). CD19 separation was made through a direct approach using magnetic beads, coated with a monoclonal antibody specific for human CD19. Mononuclear cells (10 7 ) were resuspended in 80 ml Miltenyi buffer and incubated with 20 ml beads according to manufacturer recommendation for 15 0 at 41C. Separation was performed using the Miltenyi Minimacs cell separation system (Miltenyi Biotec Gmbh, Bergisch Gladbach, Germany).
V-IgH sequencing analysis
Tumor-specific V-IgH rearrangements were amplified starting from genomic DNA as described elsewhere. [26] [27] [28] Primers and PCR conditions for V-IgH amplification were previously described. [26] [27] [28] [29] Briefly, 1 mg of genomic DNA was amplified with consensus forward primers derived from leader region together with a J consensus region antisense primer. [26] [27] [28] [29] The reaction was continued for 30-33 cycles with denaturation at 941C for 1 0 , annealing at 621C for 30 00 and extension at 721C for 30 00 , with a final extension of 10 0 at 721C. PCR products were then analyzed by electrophoresis on 2% agarose gels. When an apparently clonal PCR product was observed, the sample of interest was re-amplified on a large scale and direct-sequenced. Purification of PCR products, direct sequencing reactions and sequence analysis were performed as described elsewhere. 28, 29 V-IgH analysis for somatic mutation Mutation analysis of the V-IgH region was performed as follows: nucleotide sequences were aligned to the V-BASE sequence directory (MRC, Centre for Protein Engineering, Hills Road, Cambridge, UK) (http://www.mrc-cpe. cam.ac.uk). Percentage of homology was calculated by counting the number of mutations between the 5 0 end of FR1 and the 3 0 end of FR3, as described previously. 13 Sequences with o2% or X2% deviation from the germline V-IgH sequence were considered unmutated or mutated, respectively. 13 Starting from 2002, clinicians were aware of patients' VH-MS and this parameter might have affected therapeutic decisions.
CD38 and ZAP-70 expression by flow cytometry
CD38 surface expression was analyzed utilizing the previously described flow cytometry approach with directly conjugated antibodies. 30 The B-CLL cells (gated for double CD19 and CD5 positivity) were considered CD38-positive when 30% expressed the membrane antigen. ZAP-70 expression was measured by four-color flow cytometry (CD5, CD19, CD3/56, ZAP-70) according to a modified version of the protocol originally described by Crespo et al. 10 on fresh blood samples. The cells were fixed, permeabilized (IntraPrep, Beckman Coulter, Krefeld, Germany), and stained with the anti-ZAP-70 antibody (Invitrogen, San Diego, CA, USA). After washing with PBS-bovine serum albumin 0.1%, goat antimouse-FITC (Dako, Hamburg, Germany) was added. After washing and blocking, the cells were stained with anti-CD3-PE (clone SK7, BD Bioscience, Heidelberg, Germany), anti-CD56-PE (clone My 31, BD Bioscience), anti-CD19-ECD (clone HD237, Beckman Coulter) and anti-CD5-PC5 (clone BL1a, Beckman Coulter). The samples were washed and subsequently analyzed by flow cytometry (FACScalibur, Becton Dickinson CA, USA).
FISH analysis of chromosomal imbalances
Dual-color interphase FISH for del(13q14), þ 12q13, del(11q22-q23) and del(17p13) was performed using standard protocols. 31 In our hands, the method was highly specific as control experiments using PB mononuclear cells from 10 normal blood donors always showed less than 1% positive cells for all the imbalances considered here. For correlation with TRF-L patients were grouped as follows: good prognosis: del(13q14): standard prognosis; þ 12q13 or normal; poor prognosis: del(11q22-q23) and del(17p13).
Statistical analyses
Differences between groups were analyzed using the MannWhitney U test. Survival curves were designed according to Kaplan-Meier method. OS was calculated from the date of diagnosis until death or the last follow-up alive. TTFT was defined as the time from diagnosis to first therapy or to the last follow-up off-treatment. PFS that included only patients requiring treatment was calculated from the end of the first treatment until the start of second-line therapy or to the last follow-up in remission. Log-rank test was used to compare survival curves. The cutoff value for prognostic analysis of TRF-L has been chosen by applying Receiver-Operating Characteristic (ROC) analysis. 32 This biostatistical method allows choosing the most predictive cutoff for a given parameter within the patient population under evaluation.
Results
TRF-L determination and correlation with clinical features
High heterogeneity in terms of TRF-L was observed, with mean TRF-L of 620972461 bp s.d. Median TRF-L was 6014 bp (range 1465-16 762). The 10th, 25th, 75th and 90th percentiles were 3392, 4502, 7645 and 8795 bp, respectively (Figure 1a) . In 10 patients, both unpurified and CD19-purified samples (median purity: 98% range 97-99%) were tested to exclude bias related to the presence of non-clonal mononuclear cells. As expected, as our method is not influenced by less than 30% contaminating cells, differences were marginal (median 40 bp, range 20-160) (data not shown). TRF-L did not correlate with sex or age. This observation is in line with previous studies indicating that demographic features impacting TRF-L of normal cells have little or no effect on cancer cells telomeres. 18, 22 We evaluated any correlation between Binet staging and CD38 expression but no associations was found (Figure 1b-e) . A nonsignificant trend to an association with ZAP70 expression and poor-risk cytogenetics was found (P ¼ 0.08 and P ¼ 0.054, respectively; Figure  1f , g). As recent studies indicate that the combined use of Zap-70 and CD38 provide complementary prognostic information, we also tried to verify if the combined use of these patterns were associated with TRF-L. 33 Again, no significant difference was seen although a trend was seen for longer telomeres in Zap70-/ CD38-patients (P ¼ 0.09) (data not shown).
TRF-L in relation to VH-MS and survival analysis according to these two parameters VH-MS was attempted in all patients and was successful in 183 (91%). A total of 65 patients were unmutated and 118 were mutated. A clear correlation between TRF-L and VH-MS was found (Figure 2a ). In particular, we observed a positive correlation between TRF-L and the rate of mutation (r 2 ¼ 0,1994; Po0.0001) (Figure 2b ). TRF-L distribution of VHunmutated and VH-mutated is shown in Figure 2c .
As expected, VH-MS was an effective prognostic factor in terms of OS, TTFT and PFS (Po0.0001, Po0.005 and Po0.0005, respectively) (Figure 3a-c) . In order to verify the prognostic role of TRF-L, ROC analysis was applied to OS data in order to find the most powerful cutoff value. The value of 4250 bp was the most successful discriminator and was thus chosen as cutoff for further analysis (Figure 2c) . Overall, 33 cases (14%) with discordance between TRF-L and VH-MS was noticed; 27 (41%) among VH-unmutated and six (6%) among VH-mutated patients.
The 4250 bp cutoff point was then used to verify the prognostic value of TTFT and PFS. TRF-L appeared to be a strong prognostic indicator for all prognostic parameters (OS Po0.0001, TTFT Po0.0001 and Po0.0001, respectively) (Figure 3d-f) . Of note, the two groups of patients were wellbalanced in terms of first-line treatment delivery: single agent chemotherapy was employed in 51% of patients with long telomeres requiring therapy vs 47% of patients with short telomeres, and Fludarabine in 37 and 32%, respectively.
A direct comparison between VH-MS and TRF-L as prognostic indicators is shown in Figure 4 . The presence of short telomeres
Telomere length and CLL I Ricca et al is a very stringent indicator of poor prognosis as it allows the identification of a very high-risk population of B-CLL, which includes approximately 25% of patients. Regarding the good prognosis patients, the use of TRF-L considerably widens the population without loosing predictive power. Indeed, their median OS, TTFT and PFS are similar to those observed with VH-MS. In addition, TRF-L was successful in 100% of patients as opposed to 91% of VH-sequencing allowing categorization of patients not classified by VH-MS due to unsuccessful VH sequencing.
Outcome and features of patients with discordant TRF-L/ VH-MS profile
As the previous analysis indicated TRF-L as a more stringent outcome predictor than VH-MS, we attempted to define the outcome of discordant patients. Indeed, VH-unmutated patients with TRF-L 44250 bp showed a better outcome than VHunmutated patients with TRF-Lo4250 bp ( Figure 5 ). Despite the low number of patients, the difference was significant for OS (Po0.01) and PFS (Po0.05). In contrast, OS, TTFT and PFS of VH-unmutated discordant patients were not significantly different from those of VH-mutated patients (median OS of VHmutated patients 281 months vs median OS of discordant VH-unmutated patients 214 months P ¼ NS, median PFS of VHmutated patients 54 months vs median PFS of discordant VH-unmutated patients 29 months P ¼ NS). A similar finding was also observed for VH-mutated patients with short telomeres although the results are less certain as this population included only six patients. Of note, all these patients required treatment, with a median TTFT of 8 months (range 1-37). One died of disease progression after 6 months from diagnosis and three of the five surviving patients have already undergone several lines of therapy. We also tried to verify whether discordant cases could be identified by any specific feature of their IgH clonal rearrangement. Table 2 illustrates the features of the IgH rearrangement as well as flow cytometry and cytogenetics data in discordant patients. Discordant patients do not belong to a borderline population in terms of somatic mutation rate. Among VH-unmutated discordant patients, the median rate of homology to germline VH-sequences was 0.4%, which is not significantly different from the 0.9% value of concordant VHunmutated. In addition, among VH-unmutated discordant patients, the proportion of patients with 100% homology to VH-genes was 35%, similar to that of concordant patients (33%). Also in terms of VH usage, the population of VHunmutated discordant patients does not show any peculiarity with seven patients employing the VH-1 family and two employing the VH1-69, which is common in this patient subset.
14 Similar considerations can also be drawn for the VHmutated discordant patients. In particular, they show quite a variable homology rate (median 2.9%, range 2.4-5.2) and only one of our six patients employed the VH3-21, which has been associated to a worse outcome. [34] [35] [36] Also the flow cytometry and cytogenetic profile of discordant unmutated patients does not show any specific peculiarity. Fifteen of them had 144  132  120  108  96  84  72  60  48  36  24  12  0   144  132  120  108  96  84  72  60  48  36  24  12  0   months   months   months  months   240  216  192  168  144  120  96  72  48  24  0   months   240  216  192  168  144  120  96  72  48  24  0   288  264  240  216  192  168  144  120  96  72  48  24  0   months   288  264  240  216  192  168  144  120  96  72  48 
Discussion
This study assessed the prognostic value of TRF-L in a large panel of B-CLL patients. The results indicate that: (1) TRF-L is heterogeneous and correlates to the rate of somatic mutation, although a non-negligible proportion of discordant cases do exist (14%), particularly among VH-unmutated patients (41%); (2) TRF-L is a powerful outcome predictor in terms of TTFT, PFS and OS; (3) when discordance exists between VH-MS and TRF-L, the latter is the best outcome predictor; (4) VH-unmutated patients with long telomeres clinically behave similarly to VHmutated patients and thus should not be considered as high-risk patients.
A number of reports have suggested that TRF-L might have prognostic impact in B-CLL. 19, 20, 22 However, it has received less consideration than other parameters as it has been considered directly dependent on VH-MS. The recent study by Grabowski et al. 22 has challenged this viewpoint for the first time. This group showed not only that TRF-L has considerable prognostic impact in the OS of B-CLL, but also that it appears to be a better outcome predictor than VH-MS, at least in VH-mutated patients with short telomeres. 22 Our report confirms these data and considerably expands upon these findings. First, we find that TRF-L is not only useful to predict OS, but also very effective when earlier outcome indicators are considered. Second, we proved that categorization according to TRF-L is either applicable or stringent allowing to refine the high-risk subgroup to a population, which includes only 25% of CLL patients. Third, we demonstrate that in case of discordance TRF-L is a better outcome predictor than VH-MS. Finally, we show that the population of patients with discordant TRF-L and VH-MS does not overlap with any of the prognostic subgroups already identified by flow cytometry, cytogenetics or extensive characterization of the immunoglobulin rearrangement.
The identification of a population of unmutated patients with good outcome is particularly remarkable. Indeed, VH-unmutated patients are often treated aggressively. If our results will be confirmed also in independent series, the use of TRF-L analysis should spare over-treatment of several low-risk patients, and refine identification of patients with the most aggressive disease, who need aggressive and/or experimental management. 37, 38 The occurrence of patients whose outcome is better predicted by TRF-L than VH-MS prompted us to verify whether specific features of their VH-rearrangement could identify discordant patients. We firstly attempted to determine whether they belonged to some kind of borderline population in terms of somatic mutation rate. This was not the case, as the median homology rate for discordant VH-unmutated patients was similar as also was the rate for patients with 100% homology. A similar finding was noticed among the VH-mutated patients with short telomeres. We also explored whether concordant and discordant patients have peculiar features in terms of VH usage. Again, we found no striking peculiarity. The VH1-69 gene, very common among VH-unmutated patients, could be detected among both concordant and discordant VH-unmutated patients. 14, 39 The same applies to families frequently occurring in VH-mutated patients, although numbers are too small to be conclusive.
Another important observation is that the group of discordant VH-unmutated patients does not seem to represent a wellcharacterized population from the cytogenetic or immunophenotypic point of view. TRF-L was not significantly associated to Zap-70 expression and FISH. The weak association with Zap-70 expression should be considered cautiously as standardization is still a problem with this marker. 40 The poor association with FISH is also surprising as Krö ber et al. 36 reported this association for cytogenetics (Krober A, Grabowski P, Buhler A, Seiler T, Telomere length and CLL I Ricca et al However, a trend in this direction was noticed. Nevertheless, only eight discordant VH-unmutated patients had a low Zap-70 expression, indicating that this poor-risk population does not overlap with the Zap-70/VH-MS discordant population recently identified by Krö ber et al. 36 Radically, different methodological approaches have been used to observe the prognostic value of TRF-L. Damle et al. 21 used flow-FISH, Grabowski et al. 22 used real-time PCR, whereas we employed Southern blot. There are several differences in these strategies: our approach is both simple and very robust as it is minimally affected by contaminating tumor cells. 18 Realtime PCR and flow-FISH have other advantages, including requiring very small numbers of cells and having a greater potential for use in automated large-scale screening. Despite these remarkable technical differences, all these studies demonstrate the prognostic value of TRF-L in B-CLL. This strengthens the value of the finding and suggests the potential clinical use of this approach.
VH-MS is known to be stable over time. This is an advantage, as it can be assessed at any time during the long natural history of B-CLL. On the other hand, it means that the occurrence of additional genetic lesions in a VH-mutated patient might annul the prognostic power of this parameter. TRF-L is known to be less stable over time. Remes et al. 41 observed that telomeres might have different length at relapse compared to disease onset in lymphoma patients, whereas it has been shown that telomeres in monoclonal gammopathy of uncertain significance (MGUS) patients and in normal plasma cells are longer than in myeloma patients. [41] [42] [43] We have preliminary findings indicating that TRF-L is not always stable over time in CLL patients as well (Ricca et al., unpublished observation). These characteristics have two basic implications for CLL studies: first, TRF-L should be assessed before treatment, at least until more data on the prognostic value of delayed assessment are available. Second, if TRF-L is influenced by the natural history of the disease, it is reasonable that this feature might explain some of its 'added value' compared to VH-MS. For example, VH-unmutated patients with long telomeres might have a 'biologically young' tumor that still requires additional time to display its malignant behavior. Another explanation is that tumors with short telomeres need to overexpress human telomere reverse transcriptase (hTERT) in order to bypass the end replication problem. This might increase the malignant properties of cancer cells. 21, 44 The relationship among telomere length, hTERT expression and clinical outcome in CLL is the subject of currently ongoing studies at our Institution.
A final technical consideration worthy of mention is the 100% effectiveness of TRF-L assessment compared to VH-MS analysis. Despite optimal technical conditions and primer choice, some patients fail to provide a useful VH-sequence. This failure rate is around 10%. 29, 45 In these patients an important prognostic parameter is lacking. In our study, TRF-L analysis was successful in 100% of patients, stressing the method's wide applicability. In conclusion, our data stress the value of TRF-L as stringent, robust and widely applicable approach to identify high-risk CLL patients. We believe that this simple and affordable technique is thus potentially of interest for widespread clinical use.
